Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.17−0.27 (-4.96%)
Close on Nov 12, 2026Market cap $201.30MP/E –Yield –
Entrada Therapeutics cash
Cash and short-term investments held at the end of each period.
Entrada Therapeutics's cash was $193.00M at Sep 30, 2026. For fiscal 2025 it was $295.70M, down 29.6% from the year before. The highest annual figure on record is $420.00M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $295.70M | -29.6% |
| FY2024 | Dec 31, 2024 | $420.00M | +19.3% |
| FY2023 | Dec 31, 2023 | $352.00M | +86.5% |
| FY2022 | Dec 31, 2022 | $188.70M | -35.2% |
| FY2021 | Dec 31, 2021 | $291.06M | +645.5% |
| FY2020 | Dec 31, 2020 | $39.05M | +131.8% |
| FY2019 | Dec 31, 2019 | $16.84M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $193.00M | -40.9% |
| Q2 FY2026 | Jun 30, 2026 | $223.00M | -37.0% |
| Q1 FY2026 | Mar 31, 2026 | $254.90M | -33.4% |
| Q4 FY2025 | Dec 31, 2025 | $295.70M | -29.6% |
| Q3 FY2025 | Sep 30, 2025 | $326.80M | -27.3% |
| Q2 FY2025 | Jun 30, 2025 | $354.00M | -24.6% |
| Q1 FY2025 | Mar 31, 2025 | $382.50M | +16.8% |
| Q4 FY2024 | Dec 31, 2024 | $420.00M | +19.3% |
| Q3 FY2024 | Sep 30, 2024 | $449.30M | +27.1% |
| Q2 FY2024 | Jun 30, 2024 | $469.70M | +24.7% |
| Q1 FY2024 | Mar 31, 2024 | $327.40M | -20.5% |
| Q4 FY2023 | Dec 31, 2023 | $352.00M | +86.5% |
| Q3 FY2023 | Sep 30, 2023 | $353.60M | +64.0% |
| Q2 FY2023 | Jun 30, 2023 | $376.80M | +54.2% |
| Q1 FY2023 | Mar 31, 2023 | $411.60M | +56.0% |
| Q4 FY2022 | Dec 31, 2022 | $188.70M | -35.2% |
| Q3 FY2022 | Sep 30, 2022 | $215.60M | +76.5% |
| Q2 FY2022 | Jun 30, 2022 | $244.30M | +78.4% |
| Q1 FY2022 | Mar 31, 2022 | $263.90M | +80.5% |
| Q4 FY2021 | Dec 31, 2021 | $291.06M | +645.5% |
| Q3 FY2021 | Sep 30, 2021 | $122.17M | +160.1% |
| Q2 FY2021 | Jun 30, 2021 | $136.95M | +713.0% |
| Q1 FY2021 | Mar 31, 2021 | $146.19M | – |
| Q4 FY2020 | Dec 31, 2020 | $39.05M | – |
| Q3 FY2020 | Sep 30, 2020 | $46.97M | – |
| Q4 FY2019 | Dec 31, 2019 | $16.84M | – |
See a number that looks wrong?